Skip to main content
For US healthcare
professionals only.

Eyebrow Menu

  • CONTACT US
  • Important Safety Information
  • Prescribing Information
  • Instructions for Use
  • Medication Guide
  • Patient Site
Epidiolex Cannabidiol Logo

Main navigation

  • Home
  • Treatment Considerations
    • Diagnosing LGS and Dravet syndrome
    • Epilepsy in TSC
    • Why EPIDIOLEX?
  • Efficacy & Safety
    • Patient characteristics
    • LGS data
    • Dravet syndrome data
    • TSC data
    • Safety
  • Dosing
  • Getting EPIDIOLEX
    • Writing a prescription
    • Access and coverage
  • Resources
    • FAQs
    • Videos
    • Downloads
    • Patient resources
Contact Us Trigger Chatbot
×
“Can I help?”
Epidiolex Cannabidiol Logo

Sitemap

Home

Treatment considerations

Diagnosing LGS and Dravet syndrome Epilepsy in TSC Why EPIDIOLEX?

Efficacy & safety

Patient characteristics LGS data Dravet syndrome data TSC data Safety

Dosing

Getting EPIDIOLEX®
(cannabidiol)

Writing a prescription Access and coverage

 

Resources

FAQs Videos Downloads Patient resources

Contact Us

Medication Guide

Prescribing Information

Instructions for Use

BACK TO TOP

Important Safety Information & Indications

Contraindication: Hypersensitivity

EPIDIOLEX (cannabidiol) oral solution is contraindicated in patients with a history of hypersensitivity to cannabidiol or any ingredients in the product.

Warnings & Precautions

Hepatocellular Injury:

EPIDIOLEX can cause dose-related transaminase elevations. Concomitant use of valproate and elevated transaminase levels at baseline increase this risk. Transaminase and bilirubin levels should be obtained prior to starting treatment, at one, three, and six months after initiation of treatment, and periodically thereafter, or as clinically indicated. Resolution of transaminase elevations occurred with discontinuation of EPIDIOLEX, reduction of EPIDIOLEX and/or concomitant valproate, or without dose reduction. For patients with elevated transaminase levels, consider dose reduction or discontinuation of EPIDIOLEX or concomitant medications known to affect the liver (e.g., valproate or clobazam). Dose adjustment and slower dose titration is recommended in patients with moderate or severe hepatic impairment. Consider not initiating EPIDIOLEX in patients with evidence of significant liver injury.

Somnolence and Sedation:

EPIDIOLEX can cause somnolence and sedation that generally occurs early in treatment and may diminish over time; these effects occur more commonly in patients using clobazam and may be potentiated by other CNS depressants.

Suicidal Behavior and Ideation:

Antiepileptic drugs (AEDs), including EPIDIOLEX, increase the risk of suicidal thoughts or behavior. Inform patients, caregivers, and families of the risk and advise to monitor and report any signs of depression, suicidal thoughts or behavior, or unusual changes in mood or behavior. If these symptoms occur, consider if they are related to the AED or the underlying illness.

Withdrawal of Antiepileptic Drugs:

As with most AEDs, EPIDIOLEX should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus.

Adverse Reactions:

The most common adverse reactions in patients receiving EPIDIOLEX (≥10% and greater than placebo) include transaminase elevations; somnolence; decreased appetite; diarrhea; pyrexia; vomiting; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder and poor-quality sleep; and infections. Hematologic abnormalities were also observed.

Pregnancy:

EPIDIOLEX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Encourage women who are taking EPIDIOLEX during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry.

Drug Interactions:

Strong inducers of CYP3A4 and CYP2C19 may affect EPIDIOLEX exposure. EPIDIOLEX may affect exposure to CYP2C19 substrates (e.g., clobazam, diazepam, stiripentol), orally administered P-gp substrates, or other substrates (see full Prescribing Information). Consider dose reduction of orally administered everolimus, with appropriate therapeutic drug monitoring, when everolimus is combined with EPIDIOLEX. A lower starting dose of everolimus is recommended when added to EPIDIOLEX therapy. Concomitant use of EPIDIOLEX and valproate increases the incidence of liver enzyme elevations. Pneumonia was observed more frequently with concomitant use of EPIDIOLEX and clobazam. Dosage adjustment of EPIDIOLEX or other concomitant medications may be necessary.

INDICATIONS:

EPIDIOLEX (cannabidiol) oral solution is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.

Please refer to the EPIDIOLEX full Prescribing Information for additional important information.

Download the EPIDIOLEX Dosing Calculator for Android or iOS

Download Epidiolex Dosing Calculator on Apple App Store Download Epidiolex Dosing Calculator on Google Play

Footer

  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Unsubscribe
Jazz Pharmaceuticals Logo

©2022 Jazz Pharmaceuticals, Inc. All rights reserved.
US-EPX-2200685 Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries and regions. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC.

Important Safety Information & Indications

Important Safety & Indications

CONTRAINDICATION: HYPERSENSITIVITY EPIDIOLEX (cannabidiol) oral solution is contraindicated in patients with a history of hypersensitivity to cannabidiol or any ingredients in the product. WARNINGS & PRECAUTIONS Hepatocellular Injury: EPIDIOLEX can cause dose-related transaminase elevations. Concomitant use of valproate and elevated transaminase levels at baseline increase this risk. Transaminase and bilirubin levels should be obtained prior to starting treatment, at one, three, and six months after initiation of treatment, and periodically thereafter, or as clinically indicated. Resolution of…

CONTRAINDICATION: HYPERSENSITIVITY EPIDIOLEX (cannabidiol) oral solution is contraindicated in patients with a history of hypersensitivity to cannabidiol or any ingredients in the product.

You are
about
to leave EPIDIOLEXhcp.com.

Stay here Stay on Epidiolex HCP Site Let's go! Leave Epidiolex HCP Site

Jazz Pharmaceuticals is not responsible for content on external, third-party websites.

 

Please select your preferred language

English Spanish

 

EPIDIOLEX® (cannabidiol) is now approved for the treatment of TSC-associated seizures in patients 1 year of age and older, following a clinical study that showed significant reductions in TSC-associated seizures. Find out what this means for your patients and your practice.

Press Release Prescribing Information
Epidiolex Logo

Thank you for your response!

You will be directed to a relevant page on EPIDIOLEXhcp.com about a topic of your interest in a few seconds.

5

seconds